Phase 2 Study to Assess the Efficacy & Safety of Gemcitabine + Nab Paclitaxel With or Without Dociparstat in Metastatic Pancreatic Cancer Patients
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Mitesh J Borad, MD
Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic , Scottsdale Arizona
Principal InvestigatorKOL profile →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
16 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Mayo Clinic Arizona
Scottsdale, Arizona, United States
- Disney Family Cancer Center
Burbank, California, United States
- Marin Cancer Care
Greenbrae, California, United States
- Scripps Clinic Torrey Pines ( Green Hospital)
La Jolla, California, United States
- Cleveland Clinic Florida
Weston, Florida, United States
- Loyola University Medical Center/cardinal Bernardin Cancer Center
Maywood, Illinois, United States
- Indiana University Health, Goshen Center for Cancer Care
Goshen, Indiana, United States
- Fesit-Weiller Cancer Center
Shreveport, Louisiana, United States
- Saint Mary'S Health Care
Grand Rapids, Michigan, United States
- Summa Health System - Cooper Cancer Center
Akron, Ohio, United States
- Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
- Thomas Jefferson University [kimmel Cancer Center]
Philadelphia, Pennsylvania, United States
- Upmc Cancer Center
Pittsburgh, Pennsylvania, United States
- Medical University of South Carolina Hollings Cancer Center
Charleston, South Carolina, United States
- University of Texas Medical Branch
Galveston, Texas, United States
- South Texas Oncology & Hematology
San Antonio, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Nov 2011
- Primary completion
- 31 Dec 2012
- Completion
- 30 Jun 2015
- Last update posted
- 6 Jun 2022
- Registered enrollment
- 60
- Registry id
- NCT01461915
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.